OXO

Oxo Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain, dedicated to developing innovative therapeutics for female infertility. The company's primary focus is on improving embryo implantation rates, a critical bottleneck in assisted reproductive technology (ART). Its lead candidate, OXO-001, is a first-in-class, non-hormonal oral small molecule that acts directly on the endometrium to enhance its receptivity. By targeting the uterine environment rather than the embryo or hormonal balance, Oxo Therapeutics aims to provide a novel solution for women undergoing IVF or egg donation who face repeated implantation failures. Recent Phase 2 clinical data demonstrated a significant increase in live birth rates, positioning the company as a leader in the next generation of fertility treatments.